These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

627 related articles for article (PubMed ID: 27708104)

  • 1. High-resolution interrogation of functional elements in the noncoding genome.
    Sanjana NE; Wright J; Zheng K; Shalem O; Fontanillas P; Joung J; Cheng C; Regev A; Zhang F
    Science; 2016 Sep; 353(6307):1545-1549. PubMed ID: 27708104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genome-scale CRISPR-Cas9 knockout screening in human cells.
    Shalem O; Sanjana NE; Hartenian E; Shi X; Scott DA; Mikkelson T; Heckl D; Ebert BL; Root DE; Doench JG; Zhang F
    Science; 2014 Jan; 343(6166):84-87. PubMed ID: 24336571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genome-scale activation screen identifies a lncRNA locus regulating a gene neighbourhood.
    Joung J; Engreitz JM; Konermann S; Abudayyeh OO; Verdine VK; Aguet F; Gootenberg JS; Sanjana NE; Wright JB; Fulco CP; Tseng YY; Yoon CH; Boehm JS; Lander ES; Zhang F
    Nature; 2017 Aug; 548(7667):343-346. PubMed ID: 28792927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex.
    Konermann S; Brigham MD; Trevino AE; Joung J; Abudayyeh OO; Barcena C; Hsu PD; Habib N; Gootenberg JS; Nishimasu H; Nureki O; Zhang F
    Nature; 2015 Jan; 517(7536):583-8. PubMed ID: 25494202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-Throughput Approaches to Pinpoint Function within the Noncoding Genome.
    Montalbano A; Canver MC; Sanjana NE
    Mol Cell; 2017 Oct; 68(1):44-59. PubMed ID: 28985510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancer-targeted genome editing selectively blocks innate resistance to oncokinase inhibition.
    Webster DE; Barajas B; Bussat RT; Yan KJ; Neela PH; Flockhart RJ; Kovalski J; Zehnder A; Khavari PA
    Genome Res; 2014 May; 24(5):751-60. PubMed ID: 24443471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vemurafenib.
    Flaherty KT; Yasothan U; Kirkpatrick P
    Nat Rev Drug Discov; 2011 Oct; 10(11):811-2. PubMed ID: 22037033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression.
    Romano E; Pradervand S; Paillusson A; Weber J; Harshman K; Muehlethaler K; Speiser D; Peters S; Rimoldi D; Michielin O
    Clin Cancer Res; 2013 Oct; 19(20):5749-57. PubMed ID: 23948972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of resistance to RAF inhibition in melanomas harboring a BRAF mutation.
    Chapman PB
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Creation of Novel Protein Variants with CRISPR/Cas9-Mediated Mutagenesis: Turning a Screening By-Product into a Discovery Tool.
    Donovan KF; Hegde M; Sullender M; Vaimberg EW; Johannessen CM; Root DE; Doench JG
    PLoS One; 2017; 12(1):e0170445. PubMed ID: 28118392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma.
    Kim A; Cohen MS
    Expert Opin Drug Discov; 2016 Sep; 11(9):907-16. PubMed ID: 27327499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PDGFRα up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation.
    Sabbatino F; Wang Y; Wang X; Flaherty KT; Yu L; Pepin D; Scognamiglio G; Pepe S; Kirkwood JM; Cooper ZA; Frederick DT; Wargo JA; Ferrone S; Ferrone CR
    Oncotarget; 2014 Apr; 5(7):1926-41. PubMed ID: 24732172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cellular and molecular mechanisms of carcinogenic side effects and resistance to BRAF inhibitors in metastatic melanoma with BRAFV600 mutation: state of the knowledge].
    Capovilla M
    Ann Pathol; 2013 Dec; 33(6):375-85. PubMed ID: 24331719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elucidating distinct roles for NF1 in melanomagenesis.
    Maertens O; Johnson B; Hollstein P; Frederick DT; Cooper ZA; Messiaen L; Bronson RT; McMahon M; Granter S; Flaherty K; Wargo JA; Marais R; Cichowski K
    Cancer Discov; 2013 Mar; 3(3):338-49. PubMed ID: 23171796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAF
    Lunavat TR; Cheng L; Einarsdottir BO; Olofsson Bagge R; Veppil Muralidharan S; Sharples RA; Lässer C; Gho YS; Hill AF; Nilsson JA; Lötvall J
    Proc Natl Acad Sci U S A; 2017 Jul; 114(29):E5930-E5939. PubMed ID: 28684402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of vemurafenib in a trametinib-resistant stage IV melanoma patient--letter.
    Bernhardt M; Orouji E; Larribere L; Gebhardt C; Utikal J
    Clin Cancer Res; 2014 May; 20(9):2498-9. PubMed ID: 24789037
    [No Abstract]   [Full Text] [Related]  

  • 17. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.
    Johannessen CM; Boehm JS; Kim SY; Thomas SR; Wardwell L; Johnson LA; Emery CM; Stransky N; Cogdill AP; Barretina J; Caponigro G; Hieronymus H; Murray RR; Salehi-Ashtiani K; Hill DE; Vidal M; Zhao JJ; Yang X; Alkan O; Kim S; Harris JL; Wilson CJ; Myer VE; Finan PM; Root DE; Roberts TM; Golub T; Flaherty KT; Dummer R; Weber BL; Sellers WR; Schlegel R; Wargo JA; Hahn WC; Garraway LA
    Nature; 2010 Dec; 468(7326):968-72. PubMed ID: 21107320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.
    Van Allen EM; Wagle N; Sucker A; Treacy DJ; Johannessen CM; Goetz EM; Place CS; Taylor-Weiner A; Whittaker S; Kryukov GV; Hodis E; Rosenberg M; McKenna A; Cibulskis K; Farlow D; Zimmer L; Hillen U; Gutzmer R; Goldinger SM; Ugurel S; Gogas HJ; Egberts F; Berking C; Trefzer U; Loquai C; Weide B; Hassel JC; Gabriel SB; Carter SL; Getz G; Garraway LA; Schadendorf D;
    Cancer Discov; 2014 Jan; 4(1):94-109. PubMed ID: 24265153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases.
    Niessner H; Forschner A; Klumpp B; Honegger JB; Witte M; Bornemann A; Dummer R; Adam A; Bauer J; Tabatabai G; Flaherty K; Sinnberg T; Beck D; Leiter U; Mauch C; Roesch A; Weide B; Eigentler T; Schadendorf D; Garbe C; Kulms D; Quintanilla-Martinez L; Meier F
    Cancer Med; 2013 Feb; 2(1):76-85. PubMed ID: 24133630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.
    Sun C; Wang L; Huang S; Heynen GJ; Prahallad A; Robert C; Haanen J; Blank C; Wesseling J; Willems SM; Zecchin D; Hobor S; Bajpe PK; Lieftink C; Mateus C; Vagner S; Grernrum W; Hofland I; Schlicker A; Wessels LF; Beijersbergen RL; Bardelli A; Di Nicolantonio F; Eggermont AM; Bernards R
    Nature; 2014 Apr; 508(7494):118-22. PubMed ID: 24670642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.